Rational use of antidepressant drugs

Psychotherapy and Psychosomatics

Volumn 83, Issue 4, 2014, Pages 197-204

  Fava, Giovanni A ^a,b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CLONAZEPAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; PAROXETINE; SERTRALINE; VENLAFAXINE; DULOXETINE; PLACEBO;

ANXIETY DISORDER; BIPOLAR DISORDER; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DRUG USE; HUMAN; LIFESTYLE MODIFICATION; MAINTENANCE THERAPY; MAJOR DEPRESSION; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOTHERAPY; RELAPSE; REMISSION; REVIEW; SOCIAL PHOBIA; TACHYPHYLAXIS; TREATMENT DURATION; TREATMENT RESISTANT DEPRESSION; TREATMENT WITHDRAWAL; WITHDRAWAL SYNDROME; ANXIETY DISORDERS; DEPRESSIVE DISORDER, MAJOR; CLINICAL PRACTICE; DEPRESSION; FOLLOW UP; MOOD DISORDER; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); WITHDRAWAL REFLEX;

ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; DEPRESSIVE DISORDER, MAJOR; HUMANS;

EID: 84902917488     PISSN: 00333190     EISSN: 14230348     Source Type: Journal    
DOI: 10.1159/000362803     Document Type: Review

References (79)

1. Vanderbroucke JP, Psaty BM: Benefits and risks of drug treatments: How to combine the best evidence on benefits with the best data about adverse effects. JAMA 2008; 300: 2417-2419
2. Concato J, Shah N, Horwitz RI: Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342; 1887-1892
3. Fava GA: Can long-Term treatment with antidepressant drugs worsen the course of depression?. J Clin Psychiatry 2003; 64: 123-133
4. American Psychiatric Association: Practice guideline for the treatment of patients with major depressive disorder, ed 3. Am J Psychiatry 2010; 167(suppl):1-118
5. Richardson WS, Doster LM: Comorbidity and multimorbidity need to be placed in the context of a framework of risk, responsiveness, and vulnerability. J Clin Epidemiol 2014; 67: 244-246
6. Byrne SE, Rothschild AJ: Loss of antidepressant efficacy during maintenance therapy. J Clin Psychiatry 1998; 59: 279-288
7. Baldessarini RJ, Ghaemi SN, Viguera AC: Tolerance in antidepressant treatment. Psychother Psychosom 2002; 71: 177-179
8. Fava GA, Offidani E: The mechanisms of tolerance in antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 1593-1602
9. McGrath PJ, Stewart JW, Quitkin FM, Chen Y, Alpert JE, Nierenberg AA, Fava M, Cheng J, Petkova E: Predictors of relapse in a prospective study of fluoxetine treatment of major depression. Am J Psychiatry 2006; 163: 1542-1548
10. Williams N, Simpson AN, Simpson K, Nahas Z: Relapse rates with long-Term antidepressant drug therapy: A meta-Analysis. Hum Psychopharmacol 2009; 24: 401-408
11. Rothschild AJ: The Rothschild Scale for Antidepressant Tachyphylaxis: Reliability and validity. Compr Psychiatry 2008; 49: 508-513
12. Solomon DA, Leon AC, Mueller TI, Coryell W, Teres JJ, Posternak MA, Judd LL, Endicott J, Keller MB: Tachyphylaxis in unipolar major depressive disorder. J Clin Psychiatry 2005; 66: 283-290
13. Schmidt ME, Fava M, Zhang S, Gonzales J, Raute NJ, Judge R: Treatment approaches to major depressive disorder relapse. Part I. Dose increase. Psychother Psychosom 2002; 71: 190-194
14. Franchini L, Rossini S, Bongiorno F, Spagnolo C, Smeraldi E, Zanardi R: Will a second prophylactic treatment with a higher dosage of the same antidepressant either prevent or delay new depressive episodes?. Psychiatry Res 2000; 96: 81-85
15. Fava M, Detke MJ, Balestrieri M, Wang F, Raskin J, Perahia D: Management of depression relapse: Re-initiation of duloxetine treatment or dose increase. J Psychiatry Res 2006; 40: 328-336
16. Fabbri S, Fava GA, Rafanelli C, Tomba E: Family intervention approach to loss of clinical effect during long-Term antidepressant treatment: A pilot study. J Clin Psychiatry 2007; 68: 1348-1351
17. Fava GA, Ruini C, Rafanelli C, Grandi S: Cognitive behavior approach to loss of clinical effect during long-Term antidepressant treatment: A pilot study. Am J Psychiatry 2002; 159: 2094-2095
18. Leykin Y, Amsterdam JD, DeRubeis RJ, Gallop R, Shelton RC, Hollon SD: Progressive resistance to a selective serotonin reuptake inhibitor but not to cognitive therapy in the treatment of major depression. J Consult Clin Psychol 2007; 75: 267-276
19. Amsterdam JD, Williams D, Michelson D, Adler LA, Dunner DL, Nierenberg AA, Reimherr FW, Schatzberg AF: Tachyphylaxis after repeated antidepressant drug exposure in patients with recurrent major depressive disorder. Neuropsychobiology 2009; 59: 227-233
20. Fava M, Schmidt ME, Zhang S, Gonzales J, Raute NJ, Judge R: Treatment approaches to major depressive disorder relapse. Part II. Reinitiation of antidepressant treatment. Psychother Psychosom 2002; 71: 195-199
21. di Mascio A, Meyer RE, Stifler L: Effects of imipramine on individuals varying in level of depression. Am J Psychiatry 1968; 127: 55-58
22. Cusin C, Fava M, Amsterdam JD, Quitkin FM, Reimherr FW, Beasley CM Jr, Rosenbaum JF, Perlis RH: Early symptomatic worsening during treatment with fluoxetine in major depressive disorder: Prevalence and implications. J Clin Psychiatry 2007; 68: 52-57
23. Harvey AT, Silkey BS, Kornstein SG, Clary CM: Acute worsening of chronic depression During a double-blind, randomized clinical trial of antidepressant efficacy: Differences by sex and menopausal status. J Clin Psychiatry 2007; 68: 951-958
24. El-Mallakh RS, Gao Y, Briscoe BT, Roberts JR: Antidepressant induced tardive dysphoria. Psychother Psychosom 2011; 80: 57-59
25. Fux M, Taub M, Zohar J: Emergence of depressive symptoms during treatment for panic disorder with specific 5-hydroxytryptophan reuptake inhibitors. Acta Psychiatr Scand 1993; 88: 235-237
26. Noyes R, Garvey HJ, Cook BL: Follow-up study of patients with panic disorder and agoraphobia with panic attacks treated with tricyclic antidepressants. J Affect Disord 1989; 16: 249-257
27. Raja M: Delayed loss of efficacy and depressogenic action of antidepressants. J Clin Psychopharmacol 2009; 29: 612-614
28. Tondo L, Vázquez G, Baldessarini RJ: Mania associated with antidepressant treatment: Comprehensive meta-Analytic review. Acta Psychiatr Scand 2010; 121: 404-414
29. Kukopulos A, Reginaldi D, Laddomada P, Floris G, Serra G, Tondo L: Course of the manic-depressive cycle and changes caused by treatment. Pharmakopsychiatr Neuropsychopharmakol 1980; 13: 156-167
30. Sani G, Napoletano F, Vohringer PA, Sullivan M, Simonetti A, Koukopoulos A, Girardi P, Ghaemi N: Mixed depression: Clinical features and predictors of its onset associated with antidepressant use. Psychother Psychosom 2014; 83:213-221
31. Bader CD, Dunner DL: Antidepressant-induced hypomania in treatment-resistant depression. J Psychiatr Pract 2007; 13: 233-237
32. Offidani E, Fava GA, Tomba E, Baldessarini RJ: Excessive mood elevation and behavioral activation with antidepressant treatment of juvenile depressive and anxiety disorders. Psychother Psychosom 2013; 82: 132-141
33. Kramer JC, Klein DF, Fink M: Withdrawal symptoms following discontinuation of imipramine therapy. Am J Psychiatry 1961; 118: 549-550
34. Lejoyeux M, Ad's J, Mourad I, Solomon J, Dilsaver S: Antidepressant withdrawal syndrome: Recognition, prevention and management. CNS Drugs 1996; 5: 278-292
35. Baldwin DS, Montgomery SA, Nil R, Lader M: Discontinuation symptoms in Depression and anxiety disorders. Int J Neuropsychopharmacol 2007; 10: 73-84
36. Fava GA, Bernardi M, Tomba E, Rafanelli C: Effects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia. Int J Neuropsychopharmacol 2007; 10: 835-838
37. Belaise C, Gatti A, Chouinard VA, Chouinard G: Patient online report of selective serotonin reuptake inhibitor-induced persistent postwithdrawal anxiety and mood disorders. Psychother Psychosom 2012; 81: 386-388
38. Belaise C, Gatti A, Chouinard VA, Chouinard G: Persistent post-withdrawal disorders induced by paroxetine, a selective serotonin reuptake inhibitor, and treated with specific cognitive behavioral therapy. Psychother Psychosom 2014; 83:247-248
39. Tint A, Haddad PM, Anderson IM: The effect of antidepressant tapering on the incidence of discontinuation symptoms: A randomised study. J Psychopharmacol 2008; 22: 330-332
40. Andrade C: Antidepressant-withdrawal mania. J Clin Psychiatry 2004; 15: 987-993
41. Corral M, Sivertz K, Jones BD: Transient mood elevation associated with antidepressant drug decrease. Can J Psychiatry 1987; 32: 764-767
42. Sharma V: Loss of response to antidepressants and subsequent refractoriness. J Affect Disord 2001; 64: 99-106
43. Andrews PW, Kornstein SG, Halberstadt LJ, Gardner CO, Neale MC: Blue again: Perturbational effects of antidepressants suggest monoaminergic homeostasis in major depression. Front Psychol 2011; 2: 159
44. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R: Selective publication of antidepressants trails and its influence on apparent efficacy. N Engl J Med 2008; 358: 252-260
45. Paykel ES, Hollyman JA, Freeling P, Sedgwick P: Predictors of therapeutic benefit from amitriptyline in mild depression. J Affect Disord 1988; 14: 83-95
46. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, Fawcett J: Antidepressant drug effects and depression severity. JAMA 2010; 303: 47-53
47. Fava M, Rush J, Alpert JE, Balasubramani GK, Wisniewski SR, Carmin CN, Biggs MM, Zisook S, Leuchter A, Howland R, Warden D, Trivedi MH: Difference in treatment outcome in outpatients with anxious versus nonanxious depression. Am J Psychiatry 2008; 165: 342-351
48. Fava GA, Rafanelli R, Tomba E: The clinical process in psychiatry: A clinimetric approach. J Clin Psychiatry 2012; 73: 173-184
49. Fava GA, Tomba E: New modalities of assessment and treatment planning in Depression. CNS Drugs 2010; 24: 453-465
50. Fava GA, Tomba E, Tossani E: Innovative trends in the design of therapeutic trials in psychopharmacology and psychotherapy. Prog Neuropsychopharmacol Biol Psychiatry 2013; 40: 306-311
51. Cosci F, Fava GA: Staging of mental disorders: Systematic review. Psychother Psychosom 2013; 82: 20-34
52. Rutherford B, Roose SP: A model of placebo response in antidepressant clinical trials. Am J Psychiatry 2013; 170: 723-733
53. Rackley S, Bostwick JM: Depression in medically ill patients. Psychiatr Clin North Am 2012; 35: 231-247
54. Malhi GS, Hitching R, Berk M, Boyce P, Porter R, Fritz K: Pharmacological management of unipolar depression. Acta Psychiatr Scand 2013; 127(suppl 443):6-23
55. Gartlehner G, Hansen RA, Morgan LC, Thaler K, Lux L, van Noord M, Mager U, Thieda P, Gaynes BN, Wilkins T, Strobelberger M, Lyoid S, Reichenpfader U, Lohr KN: Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder. Ann Intern Med 2011; 155: 772-785
56. Perry PJ: Pharmacotherapy for major depression with melancholic features. J Affect Disord 1996; 39: 1-6
57. Schueler YB, Koesters M, Wieseler B, Grouven U, Kromp M, Kerekes MF, Kreis J, Kaiser T, Becker T, Weinmann S: A systematic review of duloxetine and venlafaxine in major depression, including unpublished data. Acta Psychiatr Scand 2011; 123: 247-265
58. Tomba E: Nowhere patients. Psychother Psychosom 2012; 81: 69-72
59. Posternak MA, Zimmerman M: Dual reuptake inhibitors incur lower rates of tachyphylaxis than selective serotonin reuptake inhibitors. J Clin Psychiatry 2005; 66: 704-707
60. Mintz DL, Flynn DF: How (not what) to prescribe: Nonpharmacologic aspects of psychopharmacology. Psychiatr Clin North Am 2012; 35: 143-163
61. Tomba E, Fava GA: Treatment selection in Depression: The role of clinical judgment. Psychiatr Clin North Am 2012; 35: 87-98
62. Keller MB, Lavori PW, Mueller TI, Endicott J, Coryell W, Hirschfeld RMA, Shea T: Time to recovery, chronicity, and levels of psychopathology in major depression. Arch Gen Psychiatry 1992; 49: 809-816
63. Guidi J, Fava GA, Fava M, Papakostas GI: Efficacy of the sequential integration of psychotherapy and pharmacotherapy in major depressive disorder. Psychol Med 2011; 41: 321-331
64. Kaymaz N, van Os J, Loonen AJ, Nolen WA: Evidence that patients with single versus recurrent depressive episodes are differentially sensitive to treatment discontinuation: A meta-Analysis of placebo-controlled randomized trials. J Clin Psychiatry 2008; 69: 1423-1436
65. Viguera AC, Baldessarini RJ, Friedberg J: Discontinuing antidepressant treatment in major depression. Harv Rev Psychiatry 1998; 5: 293-306
66. Gardarsdottir H, van Geffen EC, Stolker JJ, Egberts TC, Heerdink ER: Does the length of the first antidepressant treatment episode influence risk and time to a second episode?. J Clin Psychopharmacol 2009; 29: 69-72
67. Gardarsdottir H, Egberts TC, Stolker JJ, Heerdink ER: Duration of antidepressant drug treatment and its influence on risk of relapse/ recurrence: Immortal and neglected time bias. Am J Epidemiol 2009; 170: 280-285
68. Moret C, Isaac M, Briley M: Problems associated with long-Term treatment with selective serotonin reuptake inhibitors. J Psychopharmacol 2009; 23: 967-974
69. Fava GA, Sonino N: Depression associated with medical illness. CNS Drugs 1996; 5: 175-189
70. Carvalho AF, Berk M, Hyphantis TN, Mc-Intyre RS: The integrative management of treatment-resistant depression. Psychother Psychosom 2014; 83: 70-88
71. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M: Acute and longer-Term outcomes in Depressed outpatients requiring one or several treatment steps: A STAR D report. Am J Psychiatry 2006; 163: 1905-1917
72. Baldwin DS, Allgulander C, Bandelow B, Ferre F, Pallanti S: An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder. World J Biol Psychiatry 2012; 13: 510-516
73. Offidani E, Guidi J, Tomba E, Fava GA: Efficacy and tolerability of benzodiazepines versus antidepressants in anxiety disorders. Psychother Psychosom 2013; 82: 355-362
74. Chouinard G: Issues in the clinical use of benzodiazepines: Potency, withdrawal and rebound. J Clin Psychiatry 2004; 65(suppl 5):7-12
75. Pollack MH, van Ameringen M, Simon N, Worthinton JW, Hoge EA, Keshaviah A, Stein MB: A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder. Am J Psychiatry 2014; 171: 44-53
76. Roy-Byrne P: Treatment in nonresponsive patients with social anxiety: Back to the future with benzodiazepines. Am J Psychiatry 2014; 171: 1-4
77. Haug TT, Blomhoff S, Hellstrom K, Holme I, Humble M, Madsbu HP, Wold JE: Exposure therapy and sertraline in social phobia. Br J Psychiatry 2003; 182: 312-318
78. Fava GA: Long-Term treatment with antidepressant drugs: The spectacular achievements of propaganda. Psychother Psychosom 2002; 71: 127-132
79. Ghaemi NS, Vohringer PA, Whitham EA: Antidepressants from a public health perspective: Re-examining effectiveness, suicide, and carcinogenicity. Acta Psychiatr Scand 2013; 127: 89-93.